2cureX Newsletter

February 10 | 2023

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, has today issued a newsletter, that can be accessed via the link at the bottom of this message.

We regularly publish such newsletters compiling recent events and news that can be of interest to our subscribers and followers.